表紙
市場調查報告書

人工呼吸器相關肺炎 (VAP) :開發平台分析

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 264097
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
人工呼吸器相關肺炎 (VAP) :開發平台分析 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 187 Pages
簡介

本報告提供人工呼吸器相關肺炎 (VAP) 的治療藥開發情形調查分析,開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物的簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

人工呼吸器相關肺炎 (VAP)的概要

治療藥的開發

  • 概要
  • 各企業
  • 企業開發中的治療藥

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aridis Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bioversys AG
  • Cumberland Pharmaceuticals Inc
  • CytaCoat AB
  • Destiny Pharma Plc
  • Dong-A Socio Holdings Co Ltd
  • EnBiotix Inc
  • Evaxion Biotech ApS
  • Hypo-Stream Ltd
  • Meiji Seika Pharma Co Ltd
  • Merck & Co Inc
  • Motif Bio Plc
  • Nabriva Therapeutics Plc
  • Nosopharm SAS
  • Peptineo
  • Polyphor AG
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Tetraphase Pharmaceuticals Inc
  • TGV-Inhalonix Inc
  • VenatoRx Pharmaceuticals Inc
  • Wockhardt Ltd

藥物簡介

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12403IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia - Pipeline Review, H2 2020, provides an overview of the Ventilator Associated Pneumonia (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 5, 8, 1, 10, 6 and 1 respectively.

Ventilator Associated Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventilator Associated Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Ventilator Associated Pneumonia (VAP) - Overview
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
  • Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Drug Profiles
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products
  • Ventilator Associated Pneumonia (VAP) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Antabio SAS, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Bioversys AG, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by CytaCoat AB, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Plc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by EnBiotix Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Helperby Therapeutics Group Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Hypo-Stream Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by La Jolla Pharmaceutical Company, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics Plc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nosopharm SAS, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Peptineo, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Pulmobiotics SL, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Spero Therapeutics Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by TGV-Inhalonix Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2020
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020